Treatment

Zidesamtinib (NVL-520) clinical trials

1 indexed studies · 1 currently recruiting

RecruitingPHASE1, PHASE2
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
This study is testing a new drug, zidesamtinib, for people with advanced cancer that has a specific genetic change called a ROS1 rearrangement. It will check how safe the drug is and if it can shrink tumours.
For: Locally Advanced Solid Tumor · Metastatic Solid Tumor
United States · Australia · Belgium